Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease

Summary

This study is a multicenter, randomized, double-blind, placebo controlled, parallel group study of a seven-week ascending dose period of SLV308 adjunctive to L-dopa treatment in patients with advanced stage Parkinson's disease (PD) and dose-dependent motor fluctuations. Patients (outpatients) will be randomized to one of three different treatment arms.

Timeline

Start

2005-10

Primary completion

—

Completion

—

Drugs

Indications